Raltegravir + Atazanavir
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Immune Deficiency Syndrome
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Trial Timeline
May 1, 2009 → Nov 1, 2013
NCT ID
NCT00814879About Raltegravir + Atazanavir
Raltegravir + Atazanavir is a pre-clinical stage product being developed by Merck for Acquired Immune Deficiency Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00814879. Target conditions include Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00814879 | Pre-clinical | Completed |
Competing Products
20 competing products in Acquired Immune Deficiency Syndrome